Literature DB >> 15113889

Prediction and identification of a permissive epitope insertion site in the vesicular stomatitis virus glycoprotein.

Lisa D Schlehuber1, John K Rose.   

Abstract

We developed a rational approach to identify a site in the vesicular stomatitis virus (VSV) glycoprotein (G) that is exposed on the protein surface and tolerant of foreign epitope insertion. The foreign epitope inserted was the six-amino-acid sequence ELDKWA, a sequence in a neutralizing epitope from human immunodeficiency virus type 1. This sequence was inserted into six sites within the VSV G protein (Indiana serotype). Four sites were selected based on hydrophilicity and high sequence variability identified by sequence comparison with other vesiculovirus G proteins. The site showing the highest variability was fully tolerant of the foreign peptide insertion. G protein containing the insertion at this site folded correctly, was transported normally to the cell surface, had normal membrane fusion activity, and could reconstitute fully infectious VSV. The virus was neutralized by the human 2F5 monoclonal antibody that binds the ELDKWA epitope. Additional studies showed that this site in G protein tolerated insertion of at least 16 amino acids while retaining full infectivity. The three other insertions in somewhat less variable sequences interfered with VSV G folding and transport to the cell surface. Two additional insertions were made in a conserved sequence adjacent to a glycosylation site and near the transmembrane domain. The former blocked G-protein transport, while the latter allowed transport to the cell surface but blocked membrane fusion activity of G protein. Identification of an insertion-tolerant site in VSV G could be important in future vaccine and targeting studies, and the general principle might also be useful in other systems.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15113889      PMCID: PMC400361          DOI: 10.1128/jvi.78.10.5079-5087.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

Authors:  N F Rose; P A Marx; A Luckay; D F Nixon; W J Moretto; S M Donahoe; D Montefiori; A Roberts; L Buonocore; J K Rose
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

2.  Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

Authors:  C E Parker; L J Deterding; C Hager-Braun; J M Binley; N Schülke; H Katinger; J P Moore; K B Tomer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  The membrane-proximal domain of vesicular stomatitis virus G protein functions as a membrane fusion potentiator and can induce hemifusion.

Authors:  E Jeetendra; Clinton S Robison; Lorraine M Albritton; Michael A Whitt
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles.

Authors:  M J Schnell; L Buonocore; E Kretzschmar; E Johnson; J K Rose
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

5.  Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge.

Authors:  A Roberts; E Kretzschmar; A S Perkins; J Forman; R Price; L Buonocore; Y Kawaoka; J K Rose
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  Ribonucleic acid synthesis of vesicular stomatitis virus, II. An RNA polymerase in the virion.

Authors:  D Baltimore; A S Huang; M Stampfer
Journal:  Proc Natl Acad Sci U S A       Date:  1970-06       Impact factor: 11.205

7.  Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.

Authors:  N F Rose; A Roberts; L Buonocore; J K Rose
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

8.  Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease.

Authors:  Jon D Reuter; Beatriz E Vivas-Gonzalez; Daniel Gomez; Jean H Wilson; Janet L Brandsma; Heather L Greenstone; John K Rose; Anjeanette Roberts
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen.

Authors:  A L Hammond; R K Plemper; J Zhang; U Schneider; S J Russell; R Cattaneo
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

10.  Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion.

Authors:  J S Kahn; M J Schnell; L Buonocore; J K Rose
Journal:  Virology       Date:  1999-02-01       Impact factor: 3.616

View more
  14 in total

1.  Selection of novel vesicular stomatitis virus glycoprotein variants from a peptide insertion library for enhanced purification of retroviral and lentiviral vectors.

Authors:  Julie H Yu; David V Schaffer
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

2.  Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line.

Authors:  Yanhua Gao; Patricia Whitaker-Dowling; Simon C Watkins; Judith A Griffin; Ira Bergman
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 3.  Understanding and altering cell tropism of vesicular stomatitis virus.

Authors:  Eric Hastie; Marcela Cataldi; Ian Marriott; Valery Z Grdzelishvili
Journal:  Virus Res       Date:  2013-06-22       Impact factor: 3.303

4.  An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins.

Authors:  Xinping Ren; Joseph Sodroski; Xinzhen Yang
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Neutralization efficiency is greatly enhanced by bivalent binding of an antibody to epitopes in the V4 region and the membrane-proximal external region within one trimer of human immunodeficiency virus type 1 glycoproteins.

Authors:  Pengcheng Wang; Xinzhen Yang
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

6.  A single amino acid change resulting in loss of fluorescence of eGFP in a viral fusion protein confers fitness and growth advantage to the recombinant vesicular stomatitis virus.

Authors:  Phat X Dinh; Debasis Panda; Phani B Das; Subash C Das; Anshuman Das; Asit K Pattnaik
Journal:  Virology       Date:  2012-07-24       Impact factor: 3.616

7.  The stem of vesicular stomatitis virus G can be replaced with the HIV-1 Env membrane-proximal external region without loss of G function or membrane-proximal external region antigenic properties.

Authors:  Ivo C Lorenz; Hanh T Nguyen; Marina Kemelman; Ross W Lindsay; Maoli Yuan; Kevin J Wright; Heather Arendt; Jaap Willem Back; Joanne DeStefano; Simon Hoffenberg; Gavin Morrow; Christy K Jurgens; Sanjay K Phogat; Timothy J Zamb; Christopher L Parks
Journal:  AIDS Res Hum Retroviruses       Date:  2014-04-09       Impact factor: 2.205

8.  Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5.

Authors:  Wu Ou; Ning Lu; Sloane S Yu; Jonathan Silver
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

9.  Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands.

Authors:  Arun Ammayappan; Kah-Whye Peng; Stephen J Russell
Journal:  J Virol       Date:  2013-10-02       Impact factor: 5.103

10.  The effects of N-terminal insertion into VSV-G of an scFv peptide.

Authors:  Hanna Dreja; Marc Piechaczyk
Journal:  Virol J       Date:  2006-09-02       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.